Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

436P - High expression of methyltransferase-like protein 11A promotes metastasis in HNSCC and is associated with immune infiltrates and poor prognosis

Date

07 Dec 2024

Session

Poster Display session

Presenters

Balachander Kannan

Citation

Annals of Oncology (2024) 35 (suppl_4): S1554-S1574. 10.1016/annonc/annonc1692

Authors

B. Kannan1, C. Pandi1, A. Pandi2, V.P. Jayaseelan2, P. Arumugam1

Author affiliations

  • 1 Molecular Biology Lab, Centre For Cellular And Molecular Research, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, 600077 - Chennai/IN
  • 2 Clinical Genetics Lab, Centre For Cellular And Molecular Research, Saveetha Dental College and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, 600077 - Chennai/IN

Resources

This content is available to ESMO members and event participants.

Abstract 436P

Background

Recent studies have highlighted the crucial role of methyltransferase-like protein 11A (METTL11A) in cancer biology. However, its role in head and neck squamous cell carcinoma (HNSCC) remains insufficiently explored.

Methods

This study aimed to investigate the expression and functional implications of METTL11A in HNSCC. We analyzed METTL11A mRNA and protein levels in tumor tissues and adjacent normal tissues from 76 HNSCC patients using RT-qPCR and western blot techniques. Additionally, we examined the association between METTL11A expression and clinical characteristics, patient prognosis, immune cell infiltration, and relevant biological pathways using data from the TCGA-HNSCC dataset.

Results

Our research found that METTL11A is significantly overexpressed in HNSCC tissues compared to normal tissues. The increased expression of METTL11A is strongly associated with nodal metastasis and poorer patient prognoses, indicating its role in cancer progression. Functional analyses showed that METTL11A is involved in critical biological pathways, emphasizing its relevance in cancer biology. Additionally, METTL11A has complex interactions with immune regulatory genes, suggesting its potential influence on the tumor immune microenvironment.

Conclusions

The overexpression of METTL11A in malignant tissues is linked to adverse clinical features and a poor prognosis in HNSCC. This identifies METTL11A as a promising prognostic marker and potential therapeutic target for HNSCC. Its involvement in immune regulation further emphasizes its significant role in this type of cancer. This study deepens our understanding of the complex factors contributing to HNSCC and paves the way for future research and clinical interventions.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

ICMR.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.